News
Merck MRK recently intensified its acquisition strategy, actively pursuing deals to enhance its development pipeline and ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
An experimental treatment called VERVE-102 lowers the amount of "bad" cholesterol in the blood of people with specific ...
We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...
Eli Lilly (NYSE: LLY) led the way in pharma M&A during June. The US pharma major announced two major deals in the month, both ...
Emerging oligonucleotides and gene editing therapies offer greater precision, long-term efficacy, and improved adherence in comparison to traditional statin therapies. This is especially true for ...
AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...
Big Pharmas like Eli Lilly, Sanofi and Novartis headed back to the dealmakers table multiple times, with 32 total deals ...
Investing.com -- BMO Capital Markets downgraded Verve Therapeutics to Market perform, saying Eli Lilly’s agreement to buy the gene-editing specialist leaves limited room for the stock to rise before ...
Verve Therapeutics, a clinical-stage biotechnology company, focuses on developing gene editing medicines for cardiovascular disease treatment, making it a strategic acquisition for Eli Lilly’s ...
The downgrade reflects Eli Lilly’s planned acquisition of Verve Therapeutics for up to $1.3 billion, according to BMO Capital.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results